37903 research outputs found
Sort by
Russell User Guide
No full textThe User Guide for the Library of Appalachian Preaching is a Google Sheet that can be searched, sorted, and downloaded for offline use.
At the moment, Russell has only one sermon in the Library; it has a Guide of its own so the records will be complete. It includes the title, sermon text, date and place the sermon was preached, and so on. This information is available in the master list of sermons as well.https://mds.marshall.edu/russell_tb/1001/thumbnail.jp
Crippling Rapid Evolution of Metastasis and Drug Resistance in A549 Non-Small Cell Lung Cancer Cells with the Clinically Relevant HSP90 Inhibitor AUY922
Get PDFThe ability for species to evolve new features in response to changing circumstances in order to survive and propagate is a ubiquitous observation on both the macroscopic and microscopic levels of living systems. It should be no surprise, then, that diseases such as cancer utilize their own forms of adaptation to perpetuate themselves when exposed to external threats. Indeed, concepts drawn from Darwinian evolution are now widely accepted to help explain certain aspects of carcinogenesis and malignant progression, the sum of which have come to be known as the theory of tumor evolution. Since metastasis and drug resistance are features that manifest toward the late stages in the disease after withstanding numerous selective pressures, cancer cells harboring these features can be viewed as the most evolutionarily fit. Just as many forms of life rely on common adaptive mechanisms to promote their survival during dramatic shifts in their environment, metastatic and drug resistant cancers may rely upon common cellular mechanisms to promote their survival when faced with untenable circumstances. We hypothesize that one of the oldest genes in the human genome, HSP90, functions as a link between metastatic and drug resistant behavior of cancer. We believe this occurs through HSP90’s relationship in supporting the function of gene products that define the cancer hallmarks and clinical evidence suggesting HSP90 is important in progressing cancer into advanced stages. In the following chapters we discuss HSP90 and its role in orchestrating evolution of metastatic and drug resistant phenotypes. We use the clinically relevant HSP90 inhibitor, AUY922, to explore our assertions in vitro in the context of non-small cell lung cancer (NSCLC), which is prone to evolving metastatic and drug resistant phenotypes. We examine the implications for our findings, future directions, and new possibilities for utilizing HSP90 inhibitors to treat cancer
Unfaithful Representation: Understating Accounts Receivable In The Name Of Conservatism
Get PDFThis research empirically examines the relationship between conservatism in accounting and the allowance for doubtful accounts. A sample of companies’ financial data related to the allowance for doubtful accounts and bad debt expense in the chemical and allied products manufacturers industry, SIC 28, for the period from 2005 through 2017 was obtained. The results of analysis of this data indicate that the allowance for doubtful accounts is overstated in these firms and has become more overstated since 2004. This research is important as few have researched the allowance for doubtful accounts, and that research has not considered the allowance for doubtful accounts as a percentage of the accounts receivable balance
Shontz User Guide
No full textThe User Guide for the Library of Appalachian Preaching is a Google Sheet that can be searched, sorted, and downloaded for offline use.
At the moment, Shontz has only one sermon in the Library; it has a Guide of its own so the records will be complete. It includes the title, sermon text, and so on. This information is available in the master list of sermons as well.https://mds.marshall.edu/shontz_vernonl/1001/thumbnail.jp
A Gompertz distribution for time scales
Get PDFWe investigate a family of probability distributions, with three parameters associated with the dynamic Gompertz function. We prove its existence for various parameter sets and discuss the existence of its time scale moments. Afterwards, we investigate the special case of discrete time scales, where it is shown that the discrete Gompertz distribution is a q -geometric distribution of the second kind. Further, we find their q -binomial moments, we bound their expected value, and we show how a classical Gompertz distribution is obtained from them
PPARα agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase
No full textPeroxisome proliferator-activated receptor α (PPARα), a fatty acid oxidation regulator, inhibits alcohol-induced fatty liver (AFL). PPARα agonist WY-14,643 ameliorates AFL. Nicotine enhances AFL. In this study, we investigated whether PPARα activation also blocks nicotine-enhanced AFL. Mice were fed liquid diets containing ethanol in the presence or absence of nicotine, WY-14,643 was added to the above diets at 10 mg/L. The results showed that WY-14,643 blunted AFL and nicotine-enhanced AFL, which was paralleled with striking induction of PPARα target genes. However, serum ALT was dramatically increased by the ethanol/WY-14,643 feeding and was further increased by nicotine/ethanol/WY-14,643 feeding, which was confirmed by necro-inflammation and elevated oxidative stress. Interestingly, serum alcohol levels were dramatically decreased by WY-14,643. Ethanol is mainly metabolized by alcohol dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1) and catalase. ADH and CYP2E1 were not increased by WY-14,643, but catalase was induced. What is more, injection of catalase inhibitor increased serum ethanol. Decreased serum alcohol, attenuated fatty liver, and enhanced liver injury were not induced by WY-14,643 in mice lacking PPARα. In conclusion, PPARα activation by WY-14,643 attenuates alcohol/nicotine-induced fatty liver but deteriorates ethanol/nicotine-induced liver injury; WY-14,643 enhances ethanol metabolism via induction of catalase
Nonpungent N-AVAM Capsaicin Analogues and Cancer Therapy
No full textCapsaicin displays robust growth-inhibitory activity in multiple human cancers. However, the feasibility of capsaicin as a clinically relevant anticancer drug is hampered by its adverse side effects. This concern has led to extensive research focused on the isolation and synthesis of second-generation nonpungent capsaicin analogues with potent antineoplastic activity. A major class of nonpungent capsaicin-like compounds belongs to the N-acyl-vanillylamide (N-AVAM) derivatives of capsaicin (hereafter referred as N-AVAM capsaicin analogues). This perspective discusses the isolation of N-AVAM capsaicin analogues from natural sources as well as their synthesis by chemical and enzymatic methods. The perspective describes the pharmacokinetic properties and anticancer activity of N-AVAM capsaicin analogues. The signaling pathways underlying the growth-inhibitory effects of N-AVAM capsaicin analogues have also been highlighted. It is hoped that the insights obtained in this perspective will facilitate the synthesis of a second generation of N-AVAM capsaicin analogues with improved stability and growth-suppressive activity in human cancer
